Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | HRH1 | P35367 | 4/20 | 0.50 |
| ▸ | HRH2 | P25021 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584267 | 0.92 | MEN1 (0.51) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL2189051 | 0.89 | CXCR4 (0.57) | CXCR4HRH3HRH1HRH2MEN1 | |
| Hydrochloric Acid SCHEMBL28701161 | 0.87 | CXCR4 (0.55) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL10927121 | 0.86 | CXCR4 (0.52) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL20332793 | 0.85 | MEN1 (0.46) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL8321073 | 0.85 | CXCR4 (0.55) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL22266289 | 0.85 | CXCR4 (0.55) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL25980827 | 0.82 | CXCR4 (0.59) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL5569626 | 0.82 | CXCR4 (0.91) | CXCR4HRH3HRH1HRH2MEN1 | |
| SCHEMBL1277016 | 0.82 | HRH3 (0.52) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389751-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2021-12-09 | — | — | US | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | CXCR4 153/4885HRH3 956/4885HRH1 1642/4885 |
| US-20210380574-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | CXCR4 3793/4885HRH3 2708/4885HRH1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.